Hydroxyurea
12 NDCs across 9 manufacturers|6 Generic,6 Brand
Hydroxyurea is used to treat brain neoplasms, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, head and neck neoplasms and hypereosinophilic syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Aug 18, 1995. FDA's Orange Book lists 5 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $14 million on Hydroxyurea across 526,000 claims for 112,000 beneficiaries.
Hydroxyurea is available as 12 NDCs from 9 manufacturers (6 generic, 6 brand), with NADAC prices from $0.19 to $62.03 per EA — the most expensive product costs about 332× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
12
6G / 6B
Manufacturers
9
competing in market
Price Spread
$0.19 – $62.03
per EA, 11 of 12 NDCs
7d Activity
avg -1.3% WoW · of 12 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
9 manufacturers producing HYDROXYUREA(2 pricing outliers)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SIKLOS 1,000 MG TABLET | $62.0318 per EA | — |
SIKLOS 100 MG TABLET | $6.2299 per EA | +0.24% |
XROMI 100 MG/ML SOLUTION | $4.9568 per ML | 0.00% |
DROXIA 400 MG CAPSULE | $0.7817 per EA | — |
DROXIA 200 MG CAPSULE | $0.7291 per EA | — |
DROXIA 300 MG CAPSULE | $0.7283 per EA | — |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
HYDROXYUREA 500 MG CAPSULE | $0.1868 per EA | -1.80% |
Frequently Asked Questions
What is Hydroxyurea used to treat?
Hydroxyurea is used to treat brain neoplasms, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, head and neck neoplasms and hypereosinophilic syndrome, per the National Library of Medicine's MED-RT classification.
When did Hydroxyurea become available as a generic?
FDA approved the first generic Hydroxyurea (ANDA) on Aug 18, 1995. The Orange Book currently lists 5 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Hydroxyurea?
In 2024, Medicare Part D spent $14 million on Hydroxyurea across 526,000 claims for 112,000 beneficiaries.
How many Hydroxyurea products are on the market?
The Hydroxyurea drug market contains 12 NDCs from 9 manufacturers — 6 generic and 6 brand products.
What is the price range for Hydroxyurea?
NADAC reference prices for Hydroxyurea range from $0.1868 to $62.0318 per EA — the most expensive product costs about 332× the cheapest. 1 additional product is priced per a different unit (e.g. liquids per ML) and isn't directly comparable.
Is generic Hydroxyurea cheaper than brand?
The average generic NADAC for Hydroxyurea is $0.1868 per EA, versus $14.1002 for brand-labeled products — brand versions average about 75× the generic price.
Which manufacturers make Hydroxyurea?
9 manufacturers list Hydroxyurea in NADAC. Ranked by number of NDCs, the largest are H2-Pharma LLC (3), Medunik (2), Nova Laboratories, Ltd. (1), Somerset Therapeutics, LLC (1), Major Pharmaceuticals (1).
How has the price of Hydroxyurea changed recently?
Over the past 7 days, 1 Hydroxyurea NDC rose and 6 fell, with a market-wide average change of -1.3%.